Harvard i-lab | Venture Incubation Program Summer 2014 Demo Day: Aldatu Biosciences | Summary and Q&A

825 views
β€’
September 10, 2014
by
Harvard Innovation Labs
YouTube video player
Harvard i-lab | Venture Incubation Program Summer 2014 Demo Day: Aldatu Biosciences

TL;DR

Aldatu Biosciences aims to provide affordable HIV drug resistance testing to improve access to optimal patient care worldwide.

Install to Summarize YouTube Videos and Get Transcripts

Key Insights

  • πŸ’— HIV drug resistance is a growing concern due to the global scale-up of access to antiretroviral drugs.
  • 😨 Limited access to HIV drug resistance testing in resource-limited healthcare settings hinders proper patient care.
  • ❓ Aldatu Biosciences' PANDA technology offers an affordable and sensitive solution to address HIV drug resistance genotyping.
  • πŸ›„ The company's focus aligns with the triple aim of healthcare improvement, aiming to reduce costs, improve outcomes, and increase access to the best care.
  • 😨 Launching in sub-Saharan Africa, where the need is the greatest, can have a significant impact on improving HIV patient care.
  • ❓ Aldatu Biosciences' innovation has been recognized and supported by the Harvard Innovation Labs, accelerating their progress and visibility.
  • πŸ«₯ The company plans to expand its product line to cater to different genotyping needs in various patient populations worldwide.

Transcript

good evening everyone my name is david reiser and i'm here with my co-founder ian mcleod to tell you about our venture aldatu biosciences hello that's who we're driven by our firsthand experiences with hiv treatment programs in africa when this young woman tesla came into the prenatal clinic she was told she was infected with hiv and the probabilit... Read More

Questions & Answers

Q: How did Aldatu Biosciences come up with the idea for affordable HIV drug resistance testing?

The founders, David Reiser and Ian McLeod, were driven by their firsthand experiences with HIV treatment programs in Africa, where they realized the limited access to testing and the consequences of resistance to standard drugs.

Q: How does PANDA, the proprietary platform technology, address the pain points of existing products?

PANDA offers affordable testing while also providing speed and sensitivity, addressing the limitations of other products in the market. It aims to provide a comprehensive solution for HIV drug resistance genotyping.

Q: What is Aldatu Biosciences' go-to-market strategy and focus?

The company plans to launch its product in sub-Saharan Africa, where the need for affordable testing is the greatest. They also aim to develop follow-on products to address distinct genotyping needs in different patient populations globally.

Q: How has the Harvard Innovation Labs (ilab) played a role in Aldatu Biosciences' journey?

The ilab provided support and resources to Aldatu Biosciences, helping them develop their plans and gain momentum. They were part of the venture incubation program and won the grand prize at the Innovation Labs Dean's Health and Life Sciences Challenge.

Summary & Key Takeaways

  • Aldatu Biosciences was founded to address the high cost and limited accessibility of HIV drug resistance testing in resource-limited healthcare settings.

  • Their proprietary platform technology, PANDA, allows for affordable and sensitive testing, increasing access to optimal HIV patient care.

  • The company is focused on reducing costs, improving outcomes, and increasing access to the best care, following the triple aim of healthcare improvement.

Share This Summary πŸ“š

Summarize YouTube Videos and Get Video Transcripts with 1-Click

Download browser extensions on:

Explore More Summaries from Harvard Innovation Labs πŸ“š

Summarize YouTube Videos and Get Video Transcripts with 1-Click

Download browser extensions on: